Caris Life Sciences Inc.
CAI | NASDAQ
$32.05
-$2.28 (-6.64%)
Nov 2, 2026, 3:58 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|
Net Income | -68.09M | -281.89M | -341.42M | -320.83M | 27.73M |
Depreciation & Amortization | 22.62M | 48.91M | 49M | 48.25M | 110.65M |
Stock-Based Compensation | 70.01M | 18.64M | 15.24M | 22.9M | 1.78M |
Other Working Capital | 6.38M | -484K | 5.22M | -8.16M | -328.31M |
Other Non-Cash Items | 91.75M | -1.8M | 8.2M | -13.78M | 452.8M |
Deferred Income Tax | n/a | n/a | n/a | n/a | 1.37M |
Change in Working Capital | -33.13M | -29.07M | -7.13M | -22.26M | -317.31M |
Operating Cash Flow | 83.16M | -245.2M | -276.1M | -285.71M | 277.02M |
Capital Expenditures | -16.26M | -8.44M | -22.32M | -42.26M | -219.45M |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | -63.4M | -378.38M | n/a |
Sales Maturities Of Investments | n/a | 61.38M | 300.49M | 137.65M | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | 185.48M |
Investing Cash Flow | -16.26M | 52.93M | 214.77M | -282.99M | -33.97M |
Debt Repayment | 16.05M | 199.82M | 10.57M | -962K | n/a |
Common Stock Repurchased | -113K | n/a | n/a | n/a | -7.95M |
Dividend Paid | n/a | n/a | n/a | n/a | -17.71M |
Other Financial Acitivies | -18.55M | 471K | -435K | 11.41M | -232.18M |
Financial Cash Flow | 664.99M | 200.29M | 10.13M | 10.45M | -249.88M |
Net Cash Flow | 732.01M | 8.02M | -51.13M | -558.25M | -6.74M |
Free Cash Flow | 66.9M | -253.64M | -298.42M | -327.96M | 57.57M |
Adj. Free Cash Flow | -3.11M | -272.29M | -313.66M | -350.86M | 55.79M |
Maintenance CapEx | n/a | n/a | n/a | -42.26M | -219.45M |
Growth CapEx | -16.26M | -8.44M | -22.32M | n/a | n/a |
Owner Earnings | 83.16M | -245.2M | -276.1M | -327.96M | 57.57M |
Add to Watchlist
Select watchlists to add or remove CAI